Companion animal cardiology represents one of the largest underserved therapeutic areas in veterinary medicine, with approximately 10% of dogs and 15% of cats developing clinically significant cardiac disease. Boehringer Ingelheim's Vetmedin (pimobendan) is the dominant cardiac therapeutic, generating $400M+ in 2025 sales. Ceva's Cardalis (benazepril/spironolactone), Vetoquinol's Forlaxo, and Zoetis's Eviplera compete in chronic disease management. Diagnostic innovation — IDEXX cardiac biomarkers, echocardiography AI, and home blood pressure monitoring — is enabling earlier disease detection and longer therapeutic windows.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Companion Animal Cardiology Market Size, Growth and Forecast 2025-2030
• Canine Cardiac Disease — DCM, MMVD, Endocardiosis
• Feline Cardiac Disease — HCM, Hypertrophic Cardiomyopathy
• Cardiac Therapeutics — Pimobendan, ACE Inhibitors, Diuretics
• Boehringer Ingelheim Vetmedin Franchise
• Cardiac Biomarkers — NT-proBNP, Troponin Diagnostics
• Echocardiography and Cardiac Imaging Innovation
• Home Blood Pressure and Heart Rate Monitoring
• Cardiac Pipeline — Novel Mechanisms and Combinations
• Veterinary Cardiology Specialist Network and Referral Dynamics
Table of Contents
1. Executive Summary
2. Market Overview
3. Companion Animal Cardiology Market Size, Growth and Forecast 2025-2030
4. Canine Cardiac Disease
5. Feline Cardiac Disease
6. Cardiac Therapeutics
7. Boehringer Vetmedin Franchise
8. Cardiac Biomarkers
9. Echocardiography and Imaging Innovation
10. Home Monitoring
11. Cardiac Pipeline
12. Veterinary Cardiology Specialist Network
13. Market Challenges and Risks
14. Competitive Landscape
15. Strategic Conclusions and Recommendations
16. Appendix
List of Tables
Table 1. Companion Animal Cardiology Market Size and Forecast 2025-2030
Table 2. Canine Cardiac Disease Prevalence by Breed and Age
Table 3. Feline Cardiac Disease Prevalence by Breed and Age
Table 4. Cardiac Therapeutic Sales by Drug Class 2023-2025
Table 5. Vetmedin Franchise Sales 2021-2025
Table 6. Cardiac Biomarker Test Volume by Supplier
Table 7. Echocardiography AI Platform Adoption
Table 8. Home Monitoring Device Sales
Table 9. Cardiac Pipeline by Mechanism and Indication
Table 10. Competitive Positioning by Therapeutic Class
Companies Profiled
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Dechra Pharmaceuticals
Elanco Animal Health
IDEXX Laboratories
Merck Animal Health
Vetoquinol
Virbac
Zoetis
